Previous close | 0.5500 |
Open | N/A |
Bid | 0.0000 |
Ask | 2.2000 |
Strike | 65.00 |
Expiry date | 2024-10-18 |
Day's range | 0.5500 - 0.5500 |
Contract range | N/A |
Volume | |
Open interest | 2 |
Key Insights Xenon Pharmaceuticals to hold its Annual General Meeting on 4th of June Total pay for CEO Ian Mortimer...
VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner (XEN1101) clinical data in major depressive disorder (MDD) at the American Society of Clinical Psychopharmacology (ASCP) 2024 Annual Meeting in Miami, FL. Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “We are pleased to present these data from our Phase 2 proof-of-
We recently compiled a list of the 7 Best Mid-Cap Healthcare Stocks To Buy Now and in this article we will look at whether hedge funds like Xenon Pharmaceuticals Inc. (NASDAQ:XENE). Challenges in the Health Sector The healthcare industry is considered to be a fairly defensive sector due to its need. According to a World […]